Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
944.58B
Market cap944.58B
Price-Earnings ratio
43.94
Price-Earnings ratio43.94
Dividend yield
0.62%
Dividend yield0.62%
Average volume
2.82M
Average volume2.82M
High today
$1,012.00
High today$1,012.00
Low today
$994.00
Low today$994.00
Open price
$1,011.36
Open price$1,011.36
Volume
1.66M
Volume1.66M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $1,000.15, with a market capitalization of 944.58B. The stock trades at a price-to-earnings (P/E) ratio of 43.94 and offers a dividend yield of 61.8%.

As of 2026-03-11, Eli Lilly(LLY) stock has fluctuated between $994.00 and $1,012.00. The current price stands at $1,000.15, placing the stock +0.6% above today's low and -1.2% off the high.

Eli Lilly(LLY) shares are trading with a volume of 1.66M, against a daily average of 2.82M.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

LLY News

Simply Wall St 4h
Eli Lilly Expands Korea Gateway Labs As Valuation Signals Potential Upside

Eli Lilly (NYSE:LLY) has partnered with Samsung Biologics to establish a new Lilly Gateway Labs site in Korea. This marks the first international expansion of...

Eli Lilly Expands Korea Gateway Labs As Valuation Signals Potential Upside
Nasdaq 1d
Eli Lilly Laps the Stock Market: Here's Why

In the latest close session, Eli Lilly (LLY) was up +1.82% at $1,008.39. This move outpaced the S&P 500's daily gain of 0.83%. Elsewhere, the Dow gained 0.5%, w...

Eli Lilly Laps the Stock Market: Here's Why
Nasdaq 2d
Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Key Points Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north o...

Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?

Analyst ratings

80%

of 35 ratings
Buy
80%
Hold
17.1%
Sell
2.9%

More LLY News

TipRanks 2d
Eli Lilly Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why

Eli Lilly and Co. (LLY) is turning to South Korea for its next big investment. The U.S. pharmaceutical giant has agreed to invest $500 million in South Korea o...

Investor's Business Daily 2d
Roche Tumbles, Taking Olema With It, On A High-Profile Failure

How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity 1/29/2026 Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss s...

Roche Tumbles, Taking Olema With It, On A High-Profile Failure
TipRanks 2d
Amazon Pharmacy expands access to Eli Lilly Zepbound KwikPen

Amazon Pharmacy (AMZN) announced expanded access to the new Zepbound KwikPen through Amazon Pharmacy. Eli Lilly’s (LLY) multi-dose injectable treatment for weig...

Simply Wall St 3d
Eli Lilly Employer Connect Launch Puts Obesity Drug Push And Rich Valuation Under The Microscope

Eli Lilly (LLY) is in focus after launching its Employer Connect platform for Zepbound, giving U.S. employers new ways to structure obesity drug coverage and wo...

Eli Lilly Employer Connect Launch Puts Obesity Drug Push And Rich Valuation Under The Microscope
The Motley Fool 4d
Where Will Eli Lilly Stock Be in 10 Years?

Eli Lilly (LLY +0.70%) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more...

Where Will Eli Lilly Stock Be in 10 Years?
The Motley Fool 4d
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?

Is Novo Nordisk (NVO 1.27%) a bargain or a value trap as it battles Eli Lilly (LLY +0.70%) for GLP‑1 leadership, execution credibility, and premium growth? Watc...

Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
TipRanks 6d
Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 1b study “A Phase 1b Study of Abemaciclib Plus Darolutamide in Men W...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.